Medtech startup Innovodigm raises Rs 5.5 crore in a seed funding round

Medtech startup Innovodigm has raised Rs 5.5 crore in a seed funding round led by the Indian Angel Network (IAN), which invested Rs 4.5 crore, with the remainder invested by PadUp Ventures. 

Advertisment

The capital will support process optimization, infrastructure scale-up, and team expansion as the startup prepares for third-party preclinical validation and clinical trials, Innovodigm said in a press statement.

Founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm is developing a proprietary Microneedle Array Patch (MAP) platform—a needle-free, thermostable method of vaccine delivery aimed at addressing limitations in traditional injectable immunization. Unlike conventional cold-chain dependent vaccines, Innovodigm’s micro-array patches contain thermostabilized vaccines that remain viable for up to 120 days at 40°C. This innovation could drastically reduce cold-storage requirements and medical waste while improving access in underserved regions.

The startup's technology has garnered early institutional validation. Its MAP platform was selected as a Top 2 Technology at the Nano Electronics Showcase 2025 organized by the Ministry of Electronics and IT. Innovodigm has also signed a Material Transfer Agreement (MTA) with an Indian vaccine manufacturer to conduct third-party validation, with clinical trials expected to commence in 2026.

A spinout from IIT Kharagpur’s Microelectronics and MEMS Lab, Innovodigm positions itself at the intersection of biomedical engineering and public health, with a focus on scalable, low-cost immunization delivery for both domestic and international markets. The startup plans to adapt its MAP for a wide range of vaccines including measles, hepatitis, influenza, and COVID-19 boosters.

As part of its long-term strategy, Innovodigm aims to build decentralized manufacturing hubs to localize production and reduce distribution bottlenecks—especially in low- and middle-income countries.